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Abstract
Background: Aim of this study is to compare the clinical and radiographic success of non-surgical endodontic
therapy in patients receiving intravenous zolendronate less than 1 year and more than 1 year.
Methods: The clinical and radiographic follow-up data of 24 patients who were receiving IV zolendronate with 37
teeth were retrieved from the archives to evaluate clinical and radiographic healing at the end of 12 months after
non-surgical endodontic therapy. The clinical and radiographic scores of teeth treated with non-surgical endodontic
therapy were analyzed.
Results: The amount of non-healed and incomplete healed teeth in patients receiving zolendronate more than 1 year
were more than the amount of teeth of non-healed and incomplete healed in patients receiving bisphosphonates less
than 1 year (p < 0.05).
Conclusions: There was a strong relationship between the duration of the bisphosphonate medication and endodontic
success.
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Background
Bisphosphonate-related osteonecrosis of the jaws (BRONJ)
is seen occasionally in bisphosphonate receiving patients
for several medical conditions such as osteoporosis, Paget’s
disease or metastatic cancer [1]. BRONJ was first described
by Marx who observed an association between long-term
bisphosphonate medication and exposed necrotic bone of
the jaws [2]. The term BRONJ was later changed to
MRONJ (medication-related osteonecrosis of the jaws) to
accommodate the growing number of gnathic osteonecro-
sis cases associated with other antiresorptive (denasumab)
and antiangiogenic drugs [3]. In position paper published
in 2009 [4], it was stated that MRONJ diagnosis is made
with the occurrence and persistence of necrotic bone on
maxilla and mandible more than 8 weeks in patients who
have been using bisphosphonates and have not received
radiation on oral and maxillofacial region. However, the
diagnosis guidelines have been changed in a latest position
paper and 3 criteria were proposed for the correct diagnosis
of MRONJ [3]. Patients may be considered to have MRONJ
if all of the following characteristics are present:
1. Current or previous treatment with antiresorptive
and/or antiangiogenic agents,
2. Exposed bone that can be probed through an
intraoral or extraoral sinus tract in the maxillofacial
region that has persisted for more than 8 weeks.
3. No history of radiation therapy to the jaws or
obvious metastatic disease to the jaws.
Surgical invasive procedures, ill-fitting partial/total
dentures or trauma are considered to be responsible
for occurrence of MRONJ [5–7]. However, the most
common trigger factor for the development of MRONJ
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is dental extraction [6, 7]. Procedures that involve dir-
ect osseous injury should be avoided in patients using
bisphosphonates. As dental extraction causes direct
trauma to the bone, dental extractions are contraindicated
if the patient is under antiresorptive drug medication [3].
If not-restorable or damaged teeth are present in bisphos-
phonate receiving patients; removal of the crown of the
damaged tooth followed by endodontic treatment of the
remaining roots is recommended [4]. Root canal treat-
ment (RCT) in bisphosphonate receiving patients is a safe
procedure and the prevalence of MRONJ may be reduced
[4]. There are several studies that encourage RCT in
patients receiving bisphosphonates [8–10]. However, suc-
cess of RCT among patients receiving bisphosphonates in
different periods has not been evaluated yet.
Aim of this study is to compare the success of non-
surgical RCT in patients receiving bisphosphonate medi-
cation less than 1 year and more than 1 year.
Methods
Study design
Thirty-two zolendronate (ZOMETA®, Novartis Pharma-
ceuticals Co., Basel, Switzerland) medicated patients who
were referred to department of endodontics from depart-
ment of oral and maxillofacial surgery for non-surgical
RCT or re-treatment of teeth with infected roots between
2008 and 2012 were selected for this retrospective study.
The current study looked retrospectively at outcomes for a
cohort of patients treated and does not report experimen-
tal or new protocols. All data analysed were collected as
part of routine diagnosis and treatment. Therefore, ethical
approval was not needed. Inclusion criteria of the cases
were as follows;
1. Single or multi root teeth treated with multiple visit
non-surgical RCT, (The root canal treatment of all
patients were finished in 2012).
2. Twelve-months follow-up period without any delay
or drop,
3. Fully achievable medical records and radiographs,
4. Patients who were ‘at risk’ stage according to
MRONJ staging category [3].
Twenty-four patients were included in the study ac-
cording to the criteria. All clinical and follow-up data of
24 patients were retrieved from the archives. All patients
had symptomatic or asymptomatic apical periodontitis
and were receiving 4 mg/3 weeks intravenous zolendro-
nate at the time of the RCT.
Endodontic therapy
Informed consent forms were read and signed by all pa-
tients prior to the RCT. All RCTs were performed by a
single endodontist with 10 years of clinical experience
using Reciproc® system (VDW GmBH, Germany) as pre-
viously described [11]. Using the instrument in a brushing
motion facilitated removal of infected debris from root ca-
nals. Same protocol was also used removing gutta-percha
remnants in retreatment cases with any additional chemi-
cals for dissolving gutta-percha cones. Working length was
determined using an electronic apex locator (Raypex 5,
VDW GmBH, Germany) with reading between the yellow
zone and apex marks. Root canals were frequently irrigated
with 2.5 % sodium hypochlorite during canal preparation
procedures. Smear layer removal protocol of sequential use
of 5 mL of 2.5 % sodium hypochlorite, 5 mL 17 % EDTA
and 2 mL 2 % chlorhexidine for 1 min with intermediate
flushing between each irrigation solution. Root canals
were filled with calcium hydroxide (Calcipast, Cerkamed
Medical Co., Stalowa Wola, Poland) as an interim dressing
for a period of 14 days. Cavities were then sealed with
cement to prevent bacterial leakage. In the second visit,
calcium hydroxide was removed by 40 % citric acid
(Cerkamed Medical Co.), root canals were dried with
paper points (Reciproc® paper points, VDW GmBH) and
canals were obturated with Reciproc® (VDW GmBH)
single gutta-percha point and root canal sealer (AHPlus®
De Trey, Konstanz, Germany) followed by sealing of
cavities with temporary cement. After 24 h, cement was
removed and cavity was incrementally restored by a single
operator with nano-hybrid resin composite (Filtek Z550,
Shade A1, 3 M Espe, USA) using two-step self-etching
adhesive system (Clearfil SE Bond, Kuraray Inc, Japan)
according to manufacturers’ instructions.
Clinical success of non-surgical RCTs was evaluated
according to the criteria as follows [9];
1. Total Healing: asymptomatic, functional tooth with
minimal or no apical lesion.
2. Functional Healing: asymptomatic, functional tooth
with apical lesion.
3. Non-Healing: symptomatic, non-functional tooth
with or without apical lesion.
X-ray evaluation
Standardized digital radiographs (RadioVisioGraphy,
Trophy Radiologie, Marne-La Vallée, France) of preopera-
tive and corresponding recall sessions were sequentially ex-
amined by three independent clinicians (O.O.E., D.O. and
I.O.) using an image-analysis software (Adobe Photoshop
CC, Adobe Systems Inc., San Jose, Calif., USA) at a magni-
fication ratio of 1:1 on a 22” plug and play LED monitor
attached to a computer equipped with NVIDIA GeForce
GTX 980 graphic card giving 2048 × 1536 pixels of reso-
lution in a 4000 K day-lit room. Inter-observer agreement
was assessed by using Cohen’s kappa test [12]. The exam-
iners were calibrated before the evaluation. Training was
conducted on images of periapical healing of 40 cases not
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present in the current study. A kappa value of 0.83 was
calculated following this calibration exercise. In case of
disagreement, images were re-evaluated until consensus
was achieved. Three examiners re-rated the same set of
radiographs for intra-observer reproducibility after 2 week
interval. The intra-observer kappa values were 0.93, 0.89,
and 0.87 respectively.
X-ray scores were set as follows;
1. Complete healing (CH): absence or no development
of apical lesion or only small changes in bone
structure on recall radiograph (Fig. 1).
2. Incomplete healing (IH): obvious reduction of apical
lesion but repair process still is incomplete on recall
radiograph (Fig. 2).
3. No healing (F): apical lesion was enlarged/unchanged,
or a new apical lesion observed on recall radiograph
(Fig. 3).
Statistical analysis
Statistical analysis was performed with SPSS 20.0 packet
program. Chi square test was used to define the differ-
ence between clinical and radiographic success levels of
non-surgical RCTs in patients receiving biphosphonates
less than 1 year and more than 1 year (p < 0.05).
Results
Clinical data of all patients is shown in Table 1. The mean
age of all patients were 60.2 (±10.9), ten patients were
male and 14 patients were female. Nineteen patients were
diagnosed with metastatic bone disease and five of them
were diagnosed with malignancy related hypercalcemia at
the time of the endodontic therapy. The total amount of
teeth that were treated with non-surgical endodontic ther-
apy was 37. Sixteen patients (76.7 %) were receiving zolen-
dronate more than 1 year and eight patients (33.3 %) were
receiving zolendronate less than 1 year. 8.1 % of 37 teeth
were treated with non-surgical re-treatment. All patients
were still receiving zolendronate at recall examinations.
The number of the teeth scored as non-healing and func-
tional healing in clinical examination of patients receiving
zolendronate more than 1 year was higher than patients
receiving zolendronate less than 1 year in the 12 month
recall examination. There was strong evidence of a rela-
tionship between the duration of zolendronate medication
and endodontic success (p < 0.05).
Similar to the clinical healing scoring, the amount of
non-healed and incomplete healed teeth in patients receiv-
ing zolendronate more than 1 year were more than non-
healed and incomplete healed teeth in patients receiving
zolendronate less than 1 year. There was a strong evidence
of a relationship between radiographic success and duration
of zolendronate medicatio006E (p < 0.05).
Discussion
Bisphosphonates are pyrophosphate analogues with anti-
resorptive properties. They can be classified into two
categories as nitrogen containing and non-nitrogen con-
taining according to structural differences in molecular
chains. Nitrogen containing bisphosphonates such as
zolendronate and pamidronate are potent molecules and
inhibit osteoclast activity more than non-nitrogen con-
taining bisphosphonates [13]. There is a positive correl-
ation between the duration and accumulative dosage of
bisphosphonates [10].
The pathophysiology of MRONJ has not been fully eluci-
dated yet [2, 14]. Several hypotheses were postulated in an
attempt to explain the pathologic mechanism of the bone
necrosis of the jaws. The unique localization of bone
necrosis in MRONJ may be attributed to major factors
such as altered bone remodeling, hampered bone resorp-
tion and constant micro trauma and auxiliary factors such
as suppression of innate and acquired immunity, soft tissue
bisphosphonate toxicity, angiogenesis inhibition and in-
flammation [5, 15–18]. Osteoclast differentiation and
function play a crucial role in bone healing and remodeling
in all skeletal bones [19]. Jaw bones have increased remod-
eling rate compared to any other skeletal bones, therefore,
bone remodeling in jaws is more easily inhibited in
bisphosphonate medicated patients, revealing healing dis-
turbances after dental procedures such as tooth extraction
and root-canal treatment [20]. Staging and management of
Fig. 1 A representative x-ray image of complete healing, a before RCT, b a-year follow-up
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MRONJ is clearly defined in the position paper in 2004 [4].
Besides an appropriate management of the disease, preven-
tion of MRONJ with a multi-disciplinary approach is an
important issue in pre-administration phase or ‘at-risk’
phase in patients receiving bisphosphonates. Several stud-
ies reported that appropriate dental screening and neces-
sary dental treatment before bisphosphonate medication
reduced the risk of MRONJ [21, 22]. In patients with
ongoing bisphosphonate medication, especially oncology
patients receiving monthly intravenous bisphosphonate
therapy, invasive dental procedures that may possess a risk
of bone damage such as tooth extraction or dentoalveolar
surgery should be avoided if possible [4]. If necrosis
develops in bisphosphonate medicated cancer patients, on-
cologist may consider to suspend bisphosphonate therapy
until healing of osteonecrosis occurs [4]. Estilo et al. [23]
reported that the interruption or decrease in bisphospho-
nate therapy did not seem to alter the course of MRONJ.
Endodontic therapy, as a conservative method, is gold
standard for the treatment of symptomatic teeth in
patients receiving bisphosphonate medication. Although
endodontic treatment is considered safe in bisphospho-
nate receiving patients, it may induce MRONJ as well [4].
Moinzadeh et al. [10] suggested that non-surgical end-
odontic treatments in patients medicated with bispho-
sphonates should be done with extreme caution due to
the risk of MRONJ. In spite of a possibility of MRONJ
development as a cause of endodontic therapy in patients
receiving bisphosphonates, it is still commonly accepted
that non-surgical endodontic treatment is much more
favorable than dental extractions in patients receiving
intravenous bisphosphonates in long periods [10].
There are a limited number of studies that investigate
the benefits of endodontic therapy in patients receiving
bisphosphonates. Hsiao et al. [9] reported that there was
no significant difference in peri-radicular healing in pa-
tients receiving and not receiving oral bisphosphonates.
In contrary, there was strong evidence of a relationship
between the duration of bisphosphonate medication and
the reduction of the periapical pathology in the current
study (p < 0.05). Hsiao et al. [9] included patients receiv-
ing oral bisphosphonates in their study. This may be the
cause of the different results of the study of Hsiao et al.
and the current study in which only patients with IV
zolendronate medication were included. The comparison
of the peri-radicular and clinical healing in patients re-
ceiving bisphosphonates for more than 1 year and less
than 1 year was made first time in the current study to
our knowledge.
The duration of bisphosphonate or antiresorptive
medication is a continuous risk factor for the develop-
ment of MRONJ regardless of the indication for the
medical therapy. The incidence of MRONJ develop-
ment among cancer patients receiving denosumab and
zolendronate was respectively 0.5–0.8 % at 1 year and
1.0–1.8 % at 2 years, 1.3–1.8 at 3 years [24]. Difference
Fig. 2 A representative x-ray image of incomplete healing, a before RCT, b a-year follow-up
Fig. 3 A representative x-ray image of non-healing, a before RCT, b a-year follow-up
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between incidences of MRONJ occurrence of 1 year and
2 years continuous antiresorptive medication is promin-
ent. Therefore, 1 year is a turning point after which the
possibility of developing MRONJ prominently increases.
However, the risk of MRONJ development among patients
who have received bisphosphonate medication for end-
odontic therapy is unknown [3]. For that particular rea-
son, in the current study, 1 year time was taken as turning
Table 1 Clinical data of all study patients
Patient # Tooth
(FDI)
Age Gender Duration of IV
zolendronat medication









Non-Healing CH IH F
1. 1 45 57 F + 12 NS-RCT + +
2. 1 44 57 F + 12 NS-RCT + +
3. 2 34 46 F + 12 NS-RCT + +
4. 2 37 46 F + 12 NS-RCT + +
5. 2 42 46 F + 12 NS-RCT + +
6. 3 45 61 M + 12 NS-RCT + +
7. 4 33 73 M + 12 NS-RCT + +
8. 5 36 47 F + 12 NS-RCT + +
9. 6 43 41 M + 12 Re-T + +
10. 6 46 41 M + 12 Re-T + +
11. 7 47 62 F + 12 NS-RCT + +
12. 8 35 56 F + 12 NS-RCT + +
13. 8 37 56 F + 12 NS-RCT + +
14. 9 21 71 M + 12 NS-RCT + +
15. 9 22 71 M + 12 NS-RCT + +
16. 10 33 49 M + 12 NS-RCT + +
17. 10 34 49 M + 12 NS-RCT + +
18. 11 31 62 F + 12 NS-RCT + +
19. 11 41 62 F + 12 NS-RCT + +
20. 12 15 81 F + 12 NS-RCT + +
21. 13 22 77 F + 12 NS-RCT + +
22. 13 23 77 F + 12 NS-RCT + +
23. 14 47 58 M + 12 NS-RCT + +
24. 15 44 55 F + 12 NS-RCT + +
25. 15 47 55 F + 12 NS-RCT + +
26. 16 33 61 F + 12 NS-RCT + +
27. 16 37 61 F + 12 NS-RCT + +
28. 17 12 79 M + 12 Re-T + +
29. 18 17 51 F + 12 NS-RCT + +
30. 18 25 51 F + 12 NS-RCT + +
31. 19 44 64 F + 12 NS-RCT + +
32. 20 42 67 M + 12 NS-RCT + +
33. 21 31 59 M + 12 NS-RCT + +
34. 22 24 46 M + 12 NS-RCT + +
35. 23 17 54 F + 12 NS-RCT + +
36. 23 14 54 F + 13 NS-RCT + +
37. 24 22 68 F + 12 NS-RCT + +
Re-T Non-surgical root canal retreatment, NS-RCT Non-surgical root canal treatment, CH Complete healing, IH Incomplete healing, F No healing
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point to evaluate the success of RCT among zolendronate
receiving patients.
Conclusion
In the current study, it can be concluded that non-surgical
endodontic therapy is more successful in patients receiv-
ing zolendronate less than 1 year. Our study is the first
study that compares the success of non-surgical RCT with
the duration of bisphosphonate medication in ‘at risk’
group of patients receiving bisphosphonates to our know-
ledge. One disadvantage of the current study is that it is a
retrospective study with limited sample size. Prospective
studies with larger sample sizes should be conducted in
order to achieve more favorable results.
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